financetom
Business
financetom
/
Business
/
Form 8.3 - Unite Group Plc
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Unite Group Plc
Oct 6, 2025 3:23 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1.

KEY INFORMATION

 

 

 

(a)

Full name of discloser:

Massachusetts Financial Services Company

 

(b)

Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

(c)

Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

UNITE GROUP PLC ( UTGPF )

 

(d)

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

 

(e)

Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

03 October 2025

 

(f)

In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

NO

 

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

 

 

Class of relevant security:

25p ordinary (GB0006928617)

 

 

Interests

Short Positions

 

 

Number

%

Number

%

 

(1)

Relevant securities owned and/or controlled:

9,258,274

1.89 %

 

 

 

(2)

Cash-settled derivatives:

 

 

 

 

 

(3)

Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

 

Total

9,258,274 *

1.89 %

 

 

 

* Massachusetts Financial Services Company and/or its affiliates do not have discretion regarding voting decisions in respect of 182,010 shares that are included in the total above.

 

 

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

 

 

 

 

(b)

Rights to subscribe for new securities (including directors’ and other employee options)

 

 

 

Class of relevant security in relation to which subscription right exists:

 

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

 

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a)

Purchases and sales

 

 

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

 

25p ordinary (GB0006928617)

Purchase

2,725

7.1950 GBP

 

25p ordinary (GB0006928617)

Sale

631

7.1921 GBP

 

 

 

(b)

Cash-settled derivative transactions

 

 

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

 

(ii)

Exercise

 

 

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

 

 

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

 

4.

OTHER INFORMATION

 

 

 

(a)

Indemnity and other dealing arrangements

 

 

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

 

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

 

 

(c)

Attachments

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

 

Date of disclosure

06 October 2025

 

Contact name

Nikki Cagan

 

Telephone number

+442074297243

 

 

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Massachusetts Financial Services Company

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Sky Uranium Notes Positive Tax Measures in Argentina as Work Continues at Amarillo Grande Project
Blue Sky Uranium Notes Positive Tax Measures in Argentina as Work Continues at Amarillo Grande Project
Aug 20, 2024
07:54 AM EDT, 08/20/2024 (MT Newswires) -- Blue Sky Uranium ( BKUCF ) said Tuesday that it expects its Amarillo Grande project in Argentina's Rio Negro province to benefit from the country's new positive tax measures. Blue Sky said the province was the first Argentine province to adopt the Incentive Regime for Large Investments under the Bases Law, which grants...
Exact Sciences's Multi-Cancer Early Detection Study Enrols First Patient
Exact Sciences's Multi-Cancer Early Detection Study Enrols First Patient
Aug 20, 2024
07:44 AM EDT, 08/20/2024 (MT Newswires) -- Exact Sciences ( EXAS ) said on Tuesday the first patient had joined its multi-cancer early detection falcon registry study at Baylor Scott & White, its primary study site in Texas. The company said the study, involving up to 25,000 patients, would assess the performance, experience, and impact of multi-cancer early detection testing...
Tonix Pharmaceuticals Begins Phase 2 Trial of Cocaine Intoxication Treatment
Tonix Pharmaceuticals Begins Phase 2 Trial of Cocaine Intoxication Treatment
Aug 20, 2024
07:58 AM EDT, 08/20/2024 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Tuesday its first patient was dosed in its phase 2, single-blind, placebo-controlled trial of TNX-1300 for treating acute cocaine intoxication in emergency departments. TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine users. The trial will assess the safety and efficacy of a single...
Tesla to get lower EU tariff on its Chinese-made EVs
Tesla to get lower EU tariff on its Chinese-made EVs
Aug 20, 2024
* EU cuts planned tariff on Tesla's China-made EV imports to 9% * Some Chinese firms in joint ventures may get reduced rates * Other planned tariffs on Chinese EVs broadly maintained * EU investigation ongoing, tariffs not in force yet * Brussels and Beijing continue negotiations (Adds detail on next steps in EU investigation in para 15 onwards) By...
Copyright 2023-2026 - www.financetom.com All Rights Reserved